Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-21-PCRP-TSA: DoD Prostate Cancer, Translational Science Award

Closed Closed July 29, 2021 Opportunity W81XWH-21-PCRP-TSA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.

• Total funding$7.2 million
• Expected awards6
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY21 PCRP Translational Science Award (TSA) mechanism supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY21 PCRP Overarching Challenges. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside, but can include a reciprocal flow of ideas and information between basic science and clinical science (bench to bedside and/or bedside to bench). This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following: • Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts. The TSA is not intended to support initial mechanistic studies of a new target. • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., an Investigational New Drug (IND) application submission • Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trials to improve clinical management of prostate cancer and/or define new areas of research • Projects that develop endpoints for clinical trials Preliminary data to support the scientific rationale and feasibility of the research approaches are required. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged. Applications should carefully consider study sample size to ensure that the study results will be able to support valid conclusions and further translation towards clinical application. It is the applicant’s responsibility to demonstrate access to the required resources or populations necessary for the study and to provide sufficient evidence that the sample size is appropriate to meet the objectives of the study. Additional guidance regarding statistical rigor for preclinical studies is provided at the end of this section.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.